UTH Analyst Ratings
Moderate Buy
10 Buy
2 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
UTH Stock 12 Month Forecast
Average Price Target
―| Highest Price TargetCHF605.81 | Average Price TargetCHF540.32 | Lowest Price TargetCHF267.12 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
UBS
CHF603.31
Buy
―
Reiterated
10/13/26
Leerink Partners
CHF570.03
Buy
―
Reiterated
10/12/26
Bank of America Securities
CHF465.17
Hold
―
Reiterated
10/09/26
J.P. Morgan
CHF571.69→CHF590.83
Buy
―
Reiterated
10/08/26
RBC Capital
CHF563.37→CHF589.17
Buy
―
Reiterated
10/08/26
Morgan Stanley
CHF471
Hold
―
Reiterated
10/07/26
BTIG
CHF605.81
Buy
―
Upgraded
10/01/26
Jefferies
CHF585.84
Buy
―
Reiterated
10/01/26
Cantor Fitzgerald
CHF582.51
Buy
―
Initiated
09/30/26
Goldman Sachs
CHF267.12
Sell
―
Initiated
09/24/26
TD Cowen
CHF561.7
Buy
―
Reiterated
09/02/26
Wells Fargo
CHF582.51
Buy
―
Reiterated
09/02/26
H.C. Wainwright
CHF549.22
Buy
―
Reiterated
08/06/26
Raymond James
CHF582.51
Buy
―
Initiated
04/09/26
Argus Research
CHF466.01
Buy
―
Assigned
03/03/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
UBS
CHF603.31
Buy
―
Reiterated
10/13/26
Leerink Partners
CHF570.03
Buy
―
Reiterated
10/12/26
Bank of America Securities
CHF465.17
Hold
―
Reiterated
10/09/26
J.P. Morgan
CHF571.69→CHF590.83
Buy
―
Reiterated
10/08/26
RBC Capital
CHF563.37→CHF589.17
Buy
―
Reiterated
10/08/26
Morgan Stanley
CHF471
Hold
―
Reiterated
10/07/26
BTIG
CHF605.81
Buy
―
Upgraded
10/01/26
Jefferies
CHF585.84
Buy
―
Reiterated
10/01/26
Cantor Fitzgerald
CHF582.51
Buy
―
Initiated
09/30/26
Goldman Sachs
CHF267.12
Sell
―
Initiated
09/24/26
TD Cowen
CHF561.7
Buy
―
Reiterated
09/02/26
Wells Fargo
CHF582.51
Buy
―
Reiterated
09/02/26
H.C. Wainwright
CHF549.22
Buy
―
Reiterated
08/06/26
Raymond James
CHF582.51
Buy
―
Initiated
04/09/26
Argus Research
CHF466.01
Buy
―
Assigned
03/03/26
Best Analysts Covering United Therapeutics
3 Months
Success Rate
15/19 ratings generated profit
Average Return
+14.11%
Copying Roanna Ruiz's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +14.11% per trade.
1 Year
Success Rate
14/16 ratings generated profit
Average Return
+26.69%
Copying Roger Song's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +26.69% per trade.
2 Years
Success Rate
11/11 ratings generated profit
Average Return
+45.55%
Copying Jasper Hellweg's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +45.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
UTH Analyst Recommendation Trends
Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
15
16
14
16
19
Hold
5
4
3
2
3
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
20
20
17
19
23
Each month's total comprises the sum of three months' worth of ratings.
UTH Financial Forecast
UTH Stock Forecast FAQ
What is CH:UTH’s average 12-month price target, according to analysts?
Based on analyst ratings, United Therapeutics’s 12-month average price target is 540.32.
What is CH:UTH’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:UTH, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is United Therapeutics a Buy, Sell or Hold?
United Therapeutics has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 2 hold ratings and 1 sell ratings.
What is United Therapeutics’s share price target?
The average share price target for United Therapeutics is 540.32. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF605.81 ,and the lowest forecast is CHF267.12. The average share price target represents N/A Increase from the current price of N/A.
The highest analyst share price target is CHF605.81 ,and the lowest forecast is CHF267.12. The average share price target represents N/A Increase from the current price of N/A.
What do analysts say about United Therapeutics?
United Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of United Therapeutics?
To buy shares of CH:UTH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.